Warnock, D G; Ortiz, A; Mauer, M; Linthorst, G E; Oliveira, J P; Serra, A L; Marodi, L; Mignani, R; Vujkovac, B; Beitner-Johnson, D; Lemay, R; Cole, J A; Svarstad, E; Waldek, S; Germain, D P; Wanner, C (2012). Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrology, Dialysis, Transplantation, 27(3):1042-1049.
Kistler, A D; Siwy, J; Breunig, F; Jeevaratnam, P; Scherl, A; Mullen, W; Warnock, D G; Wanner, C; Hughes, D A; Mischak, H; Wüthrich, R P; Serra, A L (2011). A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy. PLoS ONE, 6(6):e20534.